These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 38420695)
1. Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia. Al-Omar HA; Almodaimegh HS; Omaer A; Alzubaidi LM; Al-Harbi B; Al-Harbi I; Hassan M; Akhtar O J Med Econ; 2024; 27(1):418-429. PubMed ID: 38420695 [TBL] [Abstract][Full Text] [Related]
2. Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia. Alluhidan M; Alabdulkarim H; Alrumaih A; Al-Turaiki A; Alshahrani A; Al-Qahtani S; Alhossan A; Al-Jedai A J Med Econ; 2023; 26(1):1455-1468. PubMed ID: 37933169 [TBL] [Abstract][Full Text] [Related]
3. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide. Urva S; Levine JA; Schneck K; Tang CC Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177 [TBL] [Abstract][Full Text] [Related]
4. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
5. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900 [TBL] [Abstract][Full Text] [Related]
6. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus. Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829 [TBL] [Abstract][Full Text] [Related]
7. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. Bradley CL; McMillin SM; Hwang AY; Sherrill CH Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094 [TBL] [Abstract][Full Text] [Related]
8. The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study. Alenzi S; Alzahrani A; Aljaloud A; Alanazi K; Alarfaj SJ Front Endocrinol (Lausanne); 2024; 15():1395651. PubMed ID: 39205685 [TBL] [Abstract][Full Text] [Related]
9. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States. Zhang X; McAdam Marx C J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958 [No Abstract] [Full Text] [Related]
10. Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Alkhatib NS; Almutairi AR; Alkhezi OS; Alfayez OM; Al Yami MS; Almohammed OA Saudi Pharm J; 2022 Apr; 30(4):433-439. PubMed ID: 35527835 [TBL] [Abstract][Full Text] [Related]
11. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin. Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model. Yuan S; Wu Y Front Public Health; 2023; 11():1201818. PubMed ID: 37744474 [TBL] [Abstract][Full Text] [Related]
13. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K; N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647 [TBL] [Abstract][Full Text] [Related]
14. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates. Reitzel SB; Bøgelund M; Basse A; Barszczewska O; Ren H Curr Med Res Opin; 2023 Aug; 39(8):1055-1060. PubMed ID: 37415503 [TBL] [Abstract][Full Text] [Related]
15. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related]
16. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. Xie Z; Hu J; Gu H; Li M; Chen J Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904 [TBL] [Abstract][Full Text] [Related]
18. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States. Mody R; Valentine WJ; Hoog M; Sharland H; Belger M J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628 [TBL] [Abstract][Full Text] [Related]
19. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management. Powell J; Taylor J Clin Ther; 2024 Mar; 46(3):289-292. PubMed ID: 38310052 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]